Literature DB >> 24756923

Copper-free click-chemistry platform to functionalize cisplatin prodrugs.

Rakesh K Pathak1, Christopher D McNitt, Vladimir V Popik, Shanta Dhar.   

Abstract

The ability to rationally design and construct a platform technology to develop new platinum(IV) [Pt(IV)] prodrugs with functionalities for installation of targeting moieties, delivery systems, fluorescent reporters from a single precursor with the ability to release biologically active cisplatin by using well-defined chemistry is critical for discovering new platinum-based therapeutics. With limited numbers of possibilities considering the sensitivity of Pt(IV) centers, we used a strain-promoted azide-alkyne cycloaddition approach to provide a platform, in which new functionalities can easily be installed on cisplatin prodrugs from a single Pt(IV) precursor. The ability of this platform to be incorporated in nanodelivery vehicle and conjugation to fluorescent reporters were also investigated.
© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  cancer; cisplatin; click chemistry; nanoparticles; prodrugs

Mesh:

Substances:

Year:  2014        PMID: 24756923      PMCID: PMC4345128          DOI: 10.1002/chem.201402573

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  37 in total

1.  Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy.

Authors:  Nagesh Kolishetti; Shanta Dhar; Pedro M Valencia; Lucy Q Lin; Rohit Karnik; Stephen J Lippard; Robert Langer; Omid C Farokhzad
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-04       Impact factor: 11.205

2.  Nanoparticles: the future for platinum drugs or a research red herring?

Authors:  Nial J Wheate
Journal:  Nanomedicine (Lond)       Date:  2012-09       Impact factor: 5.307

3.  Bioorthogonal copper-free click chemistry in vivo for tumor-targeted delivery of nanoparticles.

Authors:  Heebeom Koo; Sangmin Lee; Jin Hee Na; Sun Hwa Kim; Sei Kwang Hahn; Kuiwon Choi; Ick Chan Kwon; Seo Young Jeong; Kwangmeyung Kim
Journal:  Angew Chem Int Ed Engl       Date:  2012-10-18       Impact factor: 15.336

4.  The effect of ligand lipophilicity on the nanoparticle encapsulation of Pt(IV) prodrugs.

Authors:  Timothy C Johnstone; Stephen J Lippard
Journal:  Inorg Chem       Date:  2013-07-16       Impact factor: 5.165

Review 5.  Cellular processing of platinum anticancer drugs.

Authors:  Dong Wang; Stephen J Lippard
Journal:  Nat Rev Drug Discov       Date:  2005-04       Impact factor: 84.694

6.  Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile.

Authors:  Jeffrey Hrkach; Daniel Von Hoff; Mir Mukkaram Ali; Elizaveta Andrianova; Jason Auer; Tarikh Campbell; David De Witt; Michael Figa; Maria Figueiredo; Allen Horhota; Susan Low; Kevin McDonnell; Erick Peeke; Beadle Retnarajan; Abhimanyu Sabnis; Edward Schnipper; Jeffrey J Song; Young Ho Song; Jason Summa; Douglas Tompsett; Greg Troiano; Tina Van Geen Hoven; Jim Wright; Patricia LoRusso; Philip W Kantoff; Neil H Bander; Christopher Sweeney; Omid C Farokhzad; Robert Langer; Stephen Zale
Journal:  Sci Transl Med       Date:  2012-04-04       Impact factor: 17.956

7.  Platinum(IV) prodrugs with haloacetato ligands in the axial positions can undergo hydrolysis under biologically relevant conditions.

Authors:  Ezequiel Wexselblatt; Eylon Yavin; Dan Gibson
Journal:  Angew Chem Int Ed Engl       Date:  2013-05-17       Impact factor: 15.336

8.  Multi-Functionalization of Polymers by Strain-Promoted Cycloadditions.

Authors:  Petr A Ledin; Nagesh Kolishetti; Geert-Jan Boons
Journal:  Macromolecules       Date:  2013-10-08       Impact factor: 5.985

Review 9.  Nanocarriers as an emerging platform for cancer therapy.

Authors:  Dan Peer; Jeffrey M Karp; Seungpyo Hong; Omid C Farokhzad; Rimona Margalit; Robert Langer
Journal:  Nat Nanotechnol       Date:  2007-12       Impact factor: 39.213

Review 10.  Nanoparticle therapeutics: an emerging treatment modality for cancer.

Authors:  Mark E Davis; Zhuo Georgia Chen; Dong M Shin
Journal:  Nat Rev Drug Discov       Date:  2008-09       Impact factor: 84.694

View more
  7 in total

1.  A clickable and photocleavable lipid analogue for cell membrane delivery and release.

Authors:  Shahrina Alam; Daiane S Alves; Stuart A Whitehead; Andrew M Bayer; Christopher D McNitt; Vladimir V Popik; Francisco N Barrera; Michael D Best
Journal:  Bioconjug Chem       Date:  2015-05-15       Impact factor: 4.774

Review 2.  The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs.

Authors:  Timothy C Johnstone; Kogularamanan Suntharalingam; Stephen J Lippard
Journal:  Chem Rev       Date:  2016-02-11       Impact factor: 60.622

Review 3.  The Platin-X series: activation, targeting, and delivery.

Authors:  Uttara Basu; Bhabatosh Banik; Ru Wen; Rakesh K Pathak; Shanta Dhar
Journal:  Dalton Trans       Date:  2016-08-16       Impact factor: 4.390

Review 4.  Nanotechnology inspired tools for mitochondrial dysfunction related diseases.

Authors:  Ru Wen; Bhabatosh Banik; Rakesh K Pathak; Anil Kumar; Nagesh Kolishetti; Shanta Dhar
Journal:  Adv Drug Deliv Rev       Date:  2016-01-09       Impact factor: 15.470

5.  Detouring of cisplatin to access mitochondrial genome for overcoming resistance.

Authors:  Sean Marrache; Rakesh K Pathak; Shanta Dhar
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-07       Impact factor: 11.205

Review 6.  Exploiting azide-alkyne click chemistry in the synthesis, tracking and targeting of platinum anticancer complexes.

Authors:  Nicola J Farrer; Darren M Griffith
Journal:  Curr Opin Chem Biol       Date:  2020-01-13       Impact factor: 8.822

7.  Click Pt(IV)-Carbohydrates Pro-Drugs for Treatment of Osteosarcoma.

Authors:  Eoin Moynihan; Giada Bassi; Andrea Ruffini; Silvia Panseri; Monica Montesi; Trinidad Velasco-Torrijos; Diego Montagner
Journal:  Front Chem       Date:  2021-12-07       Impact factor: 5.221

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.